Patent Application
20240408016
The invention claims the priority of the Chinese patent application with the application number of 202111187296.9 and the title of “An injectable polyhydroxyalkanoate microsphere and a preparation method thereof” filed with the China National Intellectual Property Administration on Oct. 12, 2021, which is incorporated by reference herein in its entirety.
The invention belongs to the biomedical field, in particular relates to an injectable polyhydroxyalkanoate microsphere and a preparation method thereof.
As people get older or are affected by some diseases, the muscle and collagen tissue in the human body will have different degrees of functional degradation, resulting in skin depression, gastric reflux and other problems. Therefore, people have invented a variety of fillers to fill the depressed skin or stimulate the regeneration of muscle and collagen through foreign substances, such as hyaluronic acid, bovine collagen, etc. However, the filling effect of these substances as fillers lasts for a short period and it requires frequent reinjection to maintain their filling effect. In order to achieve long-term filling effect, people try to make microspheres by using non-biodegradable materials as filling agents, such as polyvinyl alcohol (PVA) and poly(methyl methacrylate) (PMMA), and the like. Although the filling effect of these fillers can be maintained with significantly increased period, when these materials remain in the body for too long, they will release harmful substances, thus causing a series of side effects and being harmful to human health.
In recent years, biodegradable polymer materials have come into public attention. This type of material is non-toxic and non-repellent to human body, and can be gradually degraded with human metabolism and then discharged from the body. Moreover, the degradation time can vary from one week to several years by adjusting the molecular weight and other parameters of the material.
Polyhydroxyalkanoate, or PHA for short, is a natural polymer biomaterial and an intracellular polyester synthesized by microorganisms. Because of its good biocompatibility and biodegradability, PHA is one of the most ideal biomedical materials at present. PHA has good cell compatibility with cells in vivo, cells can grow well on this scaffold, and the scaffold can be degraded into CO2 and H2O. For the convenience of injection, it is usually made into microspheres, which can be injected through a needle. Because of the existence of human phagocytes, microspheres usually have a diameter of 20 microns or more, and too large microspheres may block the needle and even cause skin rupture. Therefore, the size of microspheres used for injection is usually 60 microns or less.
In the prior art, when injectable microspheres are prepared by using PHA material, aqueous polyvinyl alcohol (PVA) solution is usually used as the aqueous phase, and the emulsification method or microfluidic method is used for the preparation of microspheres. However, the microspheres produced by this process are prone to agglomerate and adhere, forming large blocky substances, which brings inconvenience to the subsequent injection, and greatly hinders the application of biodegradable material microspheres as fillers. Therefore, a novel microsphere preparation solution is urgently needed to solve the problems of microsphere aggregation and adhesion.
In view of the above, the purpose of the invention is to provide an injectable polyhydroxyalkanoate microsphere and a preparation method thereof. The preparation method provided by the invention can effectively improve the dispersion of polyhydroxyalkanoate microspheres and overcome the problems of microsphere aggregation and adhesion; at the same time, it can effectively improve the absorbability and injectability of polyhydroxyalkanoate microspheres.
The invention provides a preparation method of injectable polyhydroxyalkanoate microspheres, including the following steps:
Preferably, the hyaluronic acid has a molecular weight of 5-500 KDa.
Preferably, the mass concentration of hyaluronic acid in the aqueous phase is 0.01%-1% (w/v).
Preferably, in step c), the volume ratio of the oil phase to the aqueous phase is 1:(10-200).
Preferably, the mass concentration of PHA material in the oil phase is 2.5%-10% (w/v);
The organic solvent is selected from one or more of dichloromethane, chloroform and ethyl acetate.
Preferably, the PHA material has a molecular weight of 10-100 KDa.
Preferably, the PHA material is natural or unnatural polyhydroxyalkanoate;
The natural or non-natural polyhydroxyalkanoate includes but is not limited to one or more of PHB, PHBV, PHBHHx, P34HB, PHBVHHx, PHHx and PHO.
Preferably, the stirring rate is 100˜500 rpm.
Preferably, the stirring is performed by using a magnetic stirrer; after the addition of the oil phase, the stirring time is ≥4 h.
The invention also provides an injectable polyhydroxyalkanoate microsphere prepared by the preparation method described in the above technical solutions.
In the preparation method provided by the invention, the PHA material is dissolved in an organic solvent to prepare an oil phase, a hyaluronic acid aqueous solution is used as an aqueous phase, the aqueous phase is stirred and the oil phase is slowly added into the aqueous phase, and then the organic solvent evaporates off under continuous stirring, and then the solid-liquid separation and drying are carried out to prepare the PHA microspheres. In the above method of the invention, the dispersion of PHA microspheres can be improved, and the resulting microspheres can be rapidly dispersed in water and the microspheres are complete in morphology, independent of each other, and there is no agglomeration phenomenon, so the needle can be prevented from being blocked and subsequent injection of the PHA microspheres as a filler is facilitated. At the same time, the polyhydroxyalkanoate microspheres prepared by the invention have good absorbability and injectability. Moreover, PHA microspheres have excellent biocompatibility and will not cause rejection reaction, and can achieve long-term filling effect.
The experimental results show that the preparation method provided by the invention has the following beneficial effects: {circle around (1)} the yield of microspheres is high: the yield of microspheres is 70% or more. {circle around (2)} Good dispersibility: The PHA microspheres prepared by the invention can be dispersed in water upon proper mixing. After standing, the microspheres show good dispersibility in water and no layering, they neither float on the upper layer of water nor settle on the bottom of water, rather they are evenly dispersed in water to form a uniform dispersion. The microspheres are observed for their morphology after the above dispersion is air dried and the results show that the microspheres are complete in morphology, independent of each other, and there is no agglomeration phenomenon, all or most of the microspheres have particle size of 60 μm or less, and they can meet the injection requirements. {circle around (3)} Good absorbability: The microspheres have an absorption rate of 85% or above by using a syringe to draw the above dispersion, showing excellent absorbability. {circle around (4)} Good injectability: Pushing a syringe and collecting the dispersion injected out, calculating the injection rate of the microspheres, and the results show that the injection rate of the microspheres is 88% or above, showing excellent injectability.
In order to more clearly explain the technical solutions in the embodiments of the invention or in the prior art, the drawings needed in the description of the embodiments or the prior art will be briefly introduced as below. It is obvious that the drawings in the following description are only examples of the invention. For a person skilled in the art, other drawings can also be obtained according to the provided drawings without any creative work.
The invention provides a preparation method of injectable polyhydroxyalkanoate microspheres, including the following steps:
The order of steps a) and b) is not limited.
In the preparation method provided by the invention, the PHA material is dissolved in an organic solvent to obtain an oil phase, a hyaluronic acid aqueous solution is used as an aqueous phase, the aqueous phase is stirred and the oil phase is slowly added into the aqueous phase, and then the organic solvent evaporates off under continuous stirring, and then the solid-liquid separation and drying are carried out to prepare the PHA microspheres. In the above method of the invention, the dispersion of PHA microspheres can be improved, and the resulting microspheres can be rapidly dispersed in water and the microspheres are complete in morphology, independent of each other, and there is no agglomeration phenomenon, so the needle can be prevented from being blocked and subsequent injection of the PHA microspheres as a filler is facilitated. At the same time, the polyhydroxyalkanoate microspheres prepared by the invention have good absorbability and injectability. Moreover, the PHA microspheres have excellent biocompatibility and will not cause rejection reaction, and can achieve long-term filling effect.
For step a): Dissolving a PHA material in an organic solvent to obtain an oil phase. In the present invention, the type of PHA material (i.e. polyhydroxyalkanoate) is not limited, as long as it is a conventional five-generation PHA commercial product in the field, specifically, natural or non-natural polyhydroxyalkanoate; More specifically, one or more of PHB (i.e. 3-hydroxybutyrate), PHBV (i.e. copolymer of hydroxybutyrate and hydroxyvalerate), PHBHHx (i.e. P3HB-co-3HHx, copolyester of 3-hydroxybutyric acid and 3-hydroxycaproic acid), P34HB (i.e. P3HB-co-4HB, copolyester of 3-hydroxybutyric acid and 4-hydroxybutyrate), PHBVHx (i.e. copolymer of 3-hydroxybutyric acid, 3-hydroxycaproic acid and 3-hydroxyvaleric acid), PHHx (i.e. polyhydroxycaproate) and PHO (i.e. polyhydroxy octanoate). In the invention, the molecular weight of the PHA material is preferably 10-100 KDa; In some embodiments of the invention, the molecular weight is 10-30 KDa, 20-100 KDa, or 10-100 KDa. The average molecular weight of the PHA material is preferably 15-80 KDa. In some embodiments of the invention, the average molecular weight is 15 KDa, 40 KDa, 50 KDa or 80 KDa.
In some embodiments of the invention, the PHA material is PHBHHx, with a molecular weight of 20-100 KDa and an average molecular weight of 50 KDa. In other embodiments of the invention, the PHA material is PHBVHHx, with a molecular weight of 20-100 KDa and an average molecular weight of 50 KDa. In other embodiments of the invention, the PHA material is PHB, with a molecular weight of 20-100 KDa and an average molecular weight of 80 KDa. In other embodiments of the invention, the PHA material is PHBV, with a molecular weight of 20-100 KDa and an average molecular weight of 40 KDa. In other embodiments of the invention, the PHA material is P34HB, with a molecular weight of 10-30 KDa and an average molecular weight of 15 KDa.
In the invention, the organic solvent is preferably one or more of dichloromethane, chloroform and ethyl acetate. The invention has no special restriction on the source of the organic solvents, as long as they are commercially available.
In the invention, the mass concentration (w/v) of the organic solution which is formed by dissolving the PHA material in an organic solvent is preferably 2.5%-10%; In some embodiments of the invention, the mass concentration is 2.5%, 5% or 10%. In the present application, the organic solution formed by dissolving PHA material in an organic solvent is used as oil phase.
For step b): Dissolving hyaluronic acid in water to obtain an aqueous phase.
In the invention, the molecular weight of the hyaluronic acid (i.e. HA) is preferably 5-500 KDa; In some embodiments of the invention, the molecular weight is 5-100 KDa, 10-200 KDa or 100-500 KDa. In the invention, the average molecular weight of the hyaluronic acid is preferably 50-300 KDa. In some embodiments of the invention, the average molecular weight is 50 KDa or 300 KDa.
In some embodiments of the invention, the hyaluronic acid has a molecular weight of 5-100 KDa, and an average molecular weight of 50 KDa. In other embodiments of the invention, the hyaluronic acid has a molecular weight of 10-200 KDa, and an average molecular weight of 50 KDa. In other embodiments of the invention, the hyaluronic acid has a molecular weight of 100-500 KDa, and an average molecular weight of 300 KDa.
In the present invention, the water is preferably distilled water or deionized water, more preferably distilled water.
In the invention, the mass concentration (w/v) of the aqueous solution formed by dissolving the hyaluronic acid in water is preferably 0.01%-1%; In some embodiments of the invention, the mass concentration is 0.5%, 5% or 10%. In the present invention, the aqueous solution formed by dissolving hyaluronic acid in water is used as the aqueous phase. In the prior art, polyvinyl alcohol (PVA) aqueous solution is usually used as the aqueous phase to prepare PHA microspheres, and the resulting PHA microspheres are prone to agglomerate and adhere in water, and are difficult to disperse quickly, whereas the present invention uses hyaluronic acid aqueous solution as the aqueous phase, which can improve the dispersion of PHA microspheres, and the resulting microspheres can be rapidly dispersed in water and the microspheres are complete in morphology, independent of each other, and there is no agglomeration phenomenon, thus the needle can be prevented from being blocked, and subsequent injection of the PHA microspheres as a filler is facilitated. At the same time, the polyhydroxyalkanoate microspheres prepared by the invention have good absorbability and injectability. Moreover, PHA microspheres have excellent biocompatibility and will not cause rejection reaction, and can achieve long-term filling effect.
In the invention, the order of the above steps a) and b) is not limited.
For step c): Adding the oil phase to the aqueous phase dropwise with stirring, thereafter evaporating off the organic solvent under continuous stirring, and then carrying out solid-liquid separation and drying to obtain PHA microspheres. In the present invention, after the oil phase and aqueous phase are obtained, the aqueous phase is stirred, and the oil phase is slowly added dropwise to the aqueous phase with the stirring. Wherein, the stirring is performed by using a magnetic stirrer. The stirring rate is 100-500 rpm, typically, the stirring rate can be but not limited to 100 rpm, 200 rpm, 300 rpm, 400 rpm or 500 rpm. The volume ratio of the oil phase to the aqueous phase is preferably 1:(10-200); In some embodiments of the invention, the volume ratio is 1:10, 1:20, 1:50, 1:100, 1:150 or 1:200.
After the addition of all the oil phase, the stirring process preferably includes: first continue to stir to form emulsion, and then continue to stir to volatilize the organic solvent. In the continuous stirring process, the stirring is performed by using a magnetic stirrer. The stirring rate is 100-500 rpm; In some embodiments of the invention, the stirring rate is 400 rpm. In the continuous stirring process, the stirring is performed by using a magnetic stirrer; The stirring rate is 100-500 rpm, typically, the stirring rate can be but not limited to 100 rpm, 200 rpm, 300 rpm, 400 rpm or 500 rpm; The time of the continuous stirring is preferably ≥4 h, more preferably 4-6 h. In some embodiments of the invention, the time of continuous stirring (for volatilizing organic solvent) after the formation of emulsion is 4 h, 5 h or 6 h. In the invention, the temperatures, at which the above adding oil phase and stirring are performed, are not limited, and they can be carried out at room temperature, specifically 10-37° C., preferably 25° C.
After the solvent is completely volatilized under continuous stirring, solid-liquid separation is carried out. The invention has no special restrictions on the manners of solid-liquid separation, which can be carried out according to the conventional method known to those skilled in the art, such as filtration.
After solid-liquid separation, water is removed by drying. In the present invention, preferably, the drying is performed by freezing first and then freeze-drying. In the invention, the drying temperature is preferably −80˜−20° C.; wherein, the freezing temperature is preferably −80˜−20° C., and the freeze-drying temperature is preferably −60˜−40° C. In some embodiments of the invention, the freezing temperature is −80˜−40° C. and the time is 6˜12 h; the freeze-drying temperature is preferably −40° C. and the time is 24 h. After the above drying treatment, PHA microspheres are obtained.
The invention also provides a PHA microsphere prepared by the preparation method described in the above technical solution.
In the preparation method provided by the invention, the PHA material is dissolved in an organic solvent to prepare an oil phase, a hyaluronic acid aqueous solution is used as an aqueous phase, the aqueous phase is stirred and the oil phase is slowly added into the aqueous phase, and then the organic solvent evaporates off under continuous stirring, and then the solid-liquid separation and drying are carried out to prepare the PHA microspheres. In the above method of the invention, the dispersion of PHA microspheres can be improved, and the resulting microspheres can be rapidly dispersed in water and the microspheres are complete in morphology, independent of each other, and there is no agglomeration phenomenon, so the needle can be prevented from being blocked and subsequent injection of the PHA microspheres as a filler is facilitated. At the same time, the polyhydroxyalkanoate microspheres prepared by the invention have good absorbability and injectability. Moreover, PHA microspheres have excellent biocompatibility and will not cause rejection reaction, and can achieve long-term filling effect.
The experimental results show that:
(1) The preparation method provided by the invention has a microsphere yield of 70% or more. The PHA microspheres prepared by the invention can be dispersed in water upon proper mixing. After standing, the microspheres show good dispersibility in water and no layering, they neither float on the upper layer of the water nor settle on the bottom of the water, rather they are evenly dispersed in water to form a uniform dispersion. The microspheres are observed for their morphology after the above dispersion is air dried and the results show that the microspheres are complete in morphology, independent of each other, and there is no agglomeration phenomenon. All or most of the microspheres have particle size of 60 μm or less, and can meet the injection requirements.
(2) A disposable 1 mL syringe with a needle with an inner diameter of 0.5 mm and a length of 19.7 mm (that is, the commonly used 1 mL syringe gun head) is used as the device for detecting the absorption rate, and 1 mL of microsphere dispersion (the dry weight of microsphere is 0.1 g, marked as M0) is used as the experimental sample. All microsphere dispersions are drawn at one time. The microsphere that can be drawn into the syringe tube is withdrawn and freeze-dried, the mass of which is M1, and the absorption rate is defined as (M1/M0)×100%. The above syringe is used to draw the above microsphere dispersion, and the microsphere absorption rate of the microspheres reaches 85% or more, showing excellent absorbability.
(3) A disposable 1 mL syringe with a needle with an inner diameter of 0.5 mm and a length of 19.7 mm (that is, the commonly used 1 mL syringe gun head) is used as the device for detecting the injection rate, and 1 mL of microsphere dispersion (the dry weight of microsphere is 0.1 g, marked as M0) is used as the experimental sample. 1 mL of microsphere dispersion is injected into the syringe tube from the rear of the syringe, all microsphere dispersion is injected out at one time, the microspheres that can be injected into the outside of the syringe tube through the needle are collected and freeze-dried, the mass of which is M2, and the injection rate is defined as (M2/M0)×100%. Pushing the syringe and collecting the dispersion injected out, calculating the injection rate of the microspheres, and the results show that the injection rate of the microspheres is 88% or more, showing excellent injectability.
In order to further understand the invention, the preferable embodiments of the invention are described with reference to the examples below. However, it should be understood that these descriptions are only for further explaining the features and advantages of the invention, and are not intended to limit the claims of the invention.
1 g of PHBHHx (molecular weight 20-100 KDa, average molecular weight 50 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Hyaluronic acid (molecular weight 5-100 KDa, average molecular weight 50 KDa) was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm. At the same time, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable PHBHHx microspheres.
According to the input amount of PHBHHx material and the amount of PHBHHx microspheres obtained, the yield of injectable PHBHHx microspheres was calculated as 93%. The freeze-dried PHBHHx microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results are shown in
1 g of PHBVHHx (molecular weight 20-100 KDa, average molecular weight 50 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Hyaluronic acid (molecular weight 10-200 KDa, average molecular weight 50 KDa) was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 4 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−40° C. for 12 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable PHBVHHx microspheres.
The yield of the obtained injectable PHBVHHx microspheres was 91%. The freeze-dried PHBVHHx microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results are shown in
1 g of PHB (molecular weight 20-100 KDa, average molecular weight 80 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Hyaluronic acid (molecular weight 100-500 KDa, average molecular weight 300 KDa) was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 6 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−40° C. for 12 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable PHB microspheres.
The yield of the obtained injectable PHB microspheres was 92%. The freeze-dried PHB microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results are shown in
1 g of PHBV (molecular weight 20-100 KDa, average molecular weight 40 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Hyaluronic acid (molecular weight 5-100 KDa, average molecular weight 50 KDa) was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−40° C. for 12 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable PHBV microspheres.
The yield of the obtained injectable PHBV microspheres was 90%. The freeze-dried PHBV microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results are shown in
1 g of P34HB (molecular weight 10-30 KDa, average molecular weight 15 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Hyaluronic acid (molecular weight 5-100 KDa, average molecular weight 50 KDa) was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−40° C. for 12 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable P34HB microspheres.
The yield of the obtained injectable P34HB microspheres was 90%. The freeze-dried P34HB microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results are shown in
0.5 g, 1 g and 2 g of PHBHHx (molecular weight 20-100 KDa, average molecular weight 50 KDa) were dissolved in 20 mL of dichloromethane, respectively, to prepare organic solutions with final concentrations of 2.5% (w/v), 5% (w/v) and 10% (w/v), which were oil phase. Hyaluronic acid (molecular weight 5-100 KDa, average molecular weight 50 KDa) was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable PHBHHx microspheres.
The yields of the obtained injectable PHBHHx microspheres were 90%, 93% and 89%, respectively. The freeze-dried PHBHHx microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results show that the obtained microspheres have good dispersion, which are spherical or ellipsoidal. As detected by particle size meter, the particle sizes are 0.4-20 μm, 1-50 μm, 1-80 μm, respectively (83% of microspheres have particle size of 1-60 μm).
1 g of PHBHHx (molecular weight 20-100 KDa, average molecular weight 50 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Hyaluronic acid (molecular weight 5-100 KDa, average molecular weight 50 KDa) was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratios of the two solutions were 1:10, 1:50 and 1:200, respectively. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form emulsions; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solutions were first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable PHBHHx microspheres.
The yields of the obtained injectable PHBHHx microspheres were 71%, 93% and 94%, respectively. The freeze-dried PHBHHx microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results show that the obtained microspheres have good dispersion, which are spherical or ellipsoidal. As detected by particle size meter, the particle sizes are 1-110 μm (58% of particles have a size of 1-60 μm), 1-50 μm, 1-50 μm, respectively.
Example 8 Preparation of microspheres with different mixing mode and stirring speed 1 g of PHBHHx (molecular weight 20-100 KDa, average molecular weight 50 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Hyaluronic acid (molecular weight 5-100 KDa, average molecular weight 50 KDa) was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using a magnetic stirrer (at 100 rpm, 400 rpm, 500 rpm, respectively) and a high-speed homogenizer (at 12000 rpm) respectively, to form emulsions; The stirring was further continued for 5 h to remove the organic solvent. Thereafter, the obtained solutions were first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable PHBHHx microspheres.
The yields of the obtained injectable PHBHHx microspheres were 77%, 93%, 89% and 99%, respectively. The freeze-dried PHBHHx microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results show that the obtained microspheres have good dispersion, which are spherical or ellipsoidal. As detected by particle size meter, the particle sizes are 5-60 μm, 1-50 μm, 1-45 μm, 0.1-10 μM (particle size is basically 10 μm or below, only 5% of particles have a particle size of 1-60 μm. The overall particle size distribution is at a level of 0.1-10 μM), respectively. It is proved that when compared with the high-speed homogenization stirring method, stirring by using the magnetic stirrer at a proper speed (100-500 rpm) in the present invention is more beneficial for obtaining a suitable particle size for human body.
1 g of PHBHHx (molecular weight 20-100 KDa, average molecular weight 50 KDa) was dissolved in 20 mL of dichloromethane, chloroform and ethyl acetate, respectively, to prepare organic solutions with a final concentration of 5% (w/v), which were the oil phases. Hyaluronic acid (molecular weight 5-100 KDa, average molecular weight 50 KDa) was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form emulsions; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable PHBHHx microspheres.
The yields of the obtained injectable PHBHHx microspheres were 93%, 92%, and 89%, respectively. The freeze-dried PHBHHx microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results show that the obtained microspheres have good dispersion, which are spherical or ellipsoidal. As detected by particle size meter, the particle sizes are 1-52 μm, 1-50 μm, 1-55 μm, respectively.
1 g of PHBHHx (molecular weight 20-100 KDa, average molecular weight 50 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phases. Hyaluronic acid (molecular weight 10-200 KDa, average molecular weight 50 KDa) was dissolved in distilled water to prepare aqueous solutions with final concentrations of 0.01% (w/v), 0.5% (w/v) and 1% (w/v), respectively, which were the aqueous phases. The aqueous phases were stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form emulsions; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain injectable PHBHHx microspheres.
The yields of the obtained injectable PHBHHx microspheres were 80%, 93%, and 87%, respectively. The freeze-dried PHBHHx microspheres were dissolved in water, and they can be dispersed in water upon proper mixing. After the water was air dried, the resultant was observed on an optical microscope. The results show that the obtained microspheres have good dispersion, which are spherical or ellipsoidal. As detected by particle size meter, the particle sizes are 3-50 μm, 1-50 μm, and 0.7-50 μm, respectively.
1 g of PHBHHx (molecular weight 20-100 KDa, average molecular weight 50 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Polyvinyl alcohol (PVA) with alcoholysis degree of 80% was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain PHBHHx microspheres.
1 g of PHBVHHx (molecular weight 20-100 KDa, average molecular weight 50 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Polyvinyl alcohol (PVA) with alcoholysis degree of 80% was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using a magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain PHBVHHx microspheres.
1 g of PHB (molecular weight 20-100 KDa, average molecular weight 80 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Polyvinyl alcohol (PVA) with alcoholysis degree of 80% was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain PHB microspheres.
1 g of PHBV (molecular weight 20-100 KDa, average molecular weight 40 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Polyvinyl alcohol (PVA) with alcoholysis degree of 80% was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain PHBV microspheres.
1 g of P34HB (molecular weight 10-30 KDa, average molecular weight 15 KDa) was dissolved in 20 mL of dichloromethane to prepare an organic solution with a final concentration of 5% (w/v), which was the oil phase. Polyvinyl alcohol (PVA) with alcoholysis degree of 80% was dissolved in distilled water to prepare an aqueous solution with a final concentration of 0.5% (w/v), which was the aqueous phase. The aqueous phase was stirred using a magnetic stirrer at a speed of 400 rpm, meanwhile, the oil phase was slowly added dropwise into the aqueous phase with stirring. The volume ratio of the two solutions was 1:50. The stirring was continued using the magnetic stirrer at a speed of 400 rpm to form an emulsion; The stirring was further continued at such speed for 5 h to remove the organic solvent. Thereafter, the obtained solution was first frozen (−80° C. for 6 h), and then freeze-dried (−40° C. for 24 h) to remove water to obtain P34HB microspheres.
0.01 g of microspheres prepared in examples 1 to 5 and comparative examples 1 to 5 were weighed, dispersed in 1 mL of distilled water, and placed in 5 mL glass bottles, respectively. After rapid mixing, they were let stand.
After standing for 30 minutes, the dispersion of the microspheres in water was observed. The results are shown in
A disposable 1 mL syringe with a needle with an inner diameter of 0.5 mm and a length of 19.7 mm (that is, the commonly used 1 ml syringe gun head) was used as the injection rate detection device, and 1 mL of microsphere dispersion (the dry weight of microsphere was 0.1 g, recorded as M0) was used as the experimental sample. 0.1 g of microspheres prepared in examples 1 to 5 and comparative examples 1 to 5 were weighed, dispersed in 1 mL distilled water, and placed in glass bottles, respectively. After rapid mixing uniformly, microsphere dispersions were formed. 1 mL of dispersion was drawn by 1 ml syringe, and the microspheres drawn in the syringe were freeze-dried respectively; The percentage of the microsphere mass (M1) drawn in the syringe in the total microsphere mass (M0) was the absorbability of microspheres (M1/M0)×100%.
The results show that the absorbabilities of the PHBHHx microspheres, PHBVHHx microspheres, PHB microspheres, PHBV microspheres and P34HB microspheres in examples 1 to 5 were 95%, 93%, 91%, 90% and 85% respectively. The absorbabilities of the PHBHHx microspheres, PHBVHHx microspheres, PHB microspheres, PHBV microspheres and P34HB microspheres in comparative examples 1 to 5 were 10%, 13%, 11%, 9% and 6% respectively. It can be seen that the absorbabilities of microspheres in examples 1 to 5 were much higher than those in comparative examples 1 to 5. Thus, it is proved that compared with the case in which the polyvinyl alcohol aqueous solution is used as the aqueous phase material, the present invention significantly improves the absorbability of microspheres by using hyaluronic acid aqueous solution as the aqueous phase material.
A disposable 1 mL syringe with a needle with an inner diameter of 0.5 mm and a length of 19.7 mm (that is, the commonly used 1 ml syringe gun head) was used as the injection rate detection device, and 1 mL of microsphere dispersion (the dry weight of microsphere was 0.1 g, recorded as M0) was used as the experimental sample. 0.1 g of microspheres prepared in examples 1 to 5 and comparative examples 1 to 5 were weighed, dispersed in 1 mL distilled water, and placed in glass bottles, respectively. After rapid mixing uniformly, microsphere dispersions were formed. The dispersions were completely injected into a 1 mL syringe, after pushing the syringe, the dispersions injected out were collected and freeze-dried, respectively, and percentage of the microsphere mass (M2) of the dispersions injected out in the total microsphere mass (M0) was calculated as the injection rate of microspheres: (M2/M0)×100%. The results show that the injection rates of the PHBHHx microspheres, PHBVHHx microspheres, PHB microspheres, PHBV microspheres and P34HB microspheres in examples 1 to 5 were 91%, 92%, 90%, 90% and 88%, respectively. The injection rates of the PHBHHx microspheres, PHBVHHx microspheres, PHB microspheres, PHBV microspheres and P34HB microspheres in comparative examples 1 to 5 were 7%, 11%, 13%, 8% and 4%, respectively. It can be seen that the injection rates of microspheres in examples 1 to 5 were much higher than those in comparative examples 1 to 5. Thus, it is proved that compared with the case in which the polyvinyl alcohol aqueous solution is used as the aqueous phase material, the present invention significantly improves the injectability of microspheres by using hyaluronic acid aqueous solution as the aqueous phase material.
The above experimental results show that the preparation method provided by the invention has the following beneficial effects: {circle around (1)} the yield of microspheres is high: the yield of microspheres is 70% or more. {circle around (2)} Good dispersibility: The PHA microspheres prepared by the invention can be dispersed in water upon proper mixing. After standing, the microspheres show good dispersibility in water and no layering, they neither float on the upper layer of water nor settle on the bottom of water, rather they are evenly dispersed in water to form a uniform dispersion. The microspheres are observed for their morphology after the above dispersion is air dried and the results show that the microspheres are complete in morphology, independent of each other, and there is no agglomeration phenomenon. All or most of the microspheres have particle size of 60 μm or less, and they can meet the injection requirements. {circle around (3)} Good absorbability: the absorption rate of the microsphere reaches 85% or more by using a syringe to draw the above dispersion, showing excellent absorbability. {circle around (4)} Good injectability: pushing a syringe and collecting the dispersion injected out, calculating the injection rate of the microspheres, and the results show that the injection rate of the microspheres is 88% or more, showing excellent injectability.
In the present application, the principle and embodiments of the invention are illustrated through specific examples and the above examples are only used to help those skilled in the art to understand the method and core idea of the invention, including the best embodiment, and also enable any person skilled in the art to practice the invention, including manufacturing and using any device or system, and implementing any combined methods. It should be noted that for a person skilled in the art, without departing from the principle of the invention, the invention can also be improved and modified in many ways, and these improvements and modifications also fall within the protection scope of the claims of the invention. The protection scope of the invention is limited by the claims, and can include other embodiments that can be conceived of by those skilled in the art. If these other embodiments have structural elements similar those described in the claims, or if they include equivalent structural elements that are not substantially different from those described in the claims, these other embodiments should also be included in the scope of the claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202111187296.9 | Oct 2021 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2022/121527 | 9/27/2022 | WO |
